Johnson & Johnson (NYSE:JNJ) Shares Sold by Phocas Financial Corp.

Posted by Defense World Staff on Mar 20th, 2023

Phocas Financial Corp. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,546 shares of the company’s stock after selling 725 shares during the period. Phocas Financial Corp.’s holdings in Johnson & Johnson were worth $2,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Sandy Cove Advisors LLC increased its position in shares of Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after acquiring an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 0.7% in the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after purchasing an additional 62 shares during the period. Mason & Associates Inc boosted its stake in shares of Johnson & Johnson by 4.9% in the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the period. Magnolia Capital Advisors LLC boosted its stake in shares of Johnson & Johnson by 0.7% in the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock valued at $1,451,000 after purchasing an additional 62 shares during the period. Finally, Oakworth Capital Inc. boosted its stake in shares of Johnson & Johnson by 0.3% in the third quarter. Oakworth Capital Inc. now owns 21,363 shares of the company’s stock valued at $3,490,000 after purchasing an additional 63 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 1.1 %

Shares of NYSE:JNJ opened at $152.38 on Monday. The stock has a market capitalization of $396.84 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.71 and a 1-year high of $186.69. The company’s fifty day moving average is $161.97 and its two-hundred day moving average is $167.96. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm’s revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.13 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday. They set a “strong-buy” rating on the stock. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.